The landscape of remote patient monitoring (RPM) is currently defined by two competing philosophies. On one hand, the federal government is doubling down on innovation. Through the 2026 Physician Fee Schedule (PFS) final rule, the Centers for Medicare & Medicaid Services (CMS) has significantly expanded RPM coverage by introducing new codes that lower traditional barriers to reimbursement. By recognizing shorter data transmission windows and lighter-touch management, CMS is signaling a clear desire for providers to find new applications for and expand access to tech-enabled care. This open-ended approach deliberately avoids rigid guardrails, instead empowering clinicians to apply RPM to a diverse array of conditions and patient situations based on their own determination of clinical necessity.
On the other hand, some major commercial payers are moving in the opposite direction. Seeking to manage the rapid growth of the RPM market, insurers like Aetna are looking toward established clinical evidence to shape more structured coverage. This shift toward "responsible boundaries" represents a move away from provider-led flexibility in favor of a more rigid, evidence-led model. Aetna’s recent RPM policy update is a prime example of this trend and underscores a clear divergence from the federal push for innovation.
Key Aetna Remote Patient Monitoring Policy Changes
A recent review of commercial payer policies on remote monitoring turned up meaningful restrictions at Aetna, one of the country's largest insurers. Aetna has narrowed the conditions that qualify for RPM coverage and does not cover remote therapeutic monitoring (RTM).
Aetna updated its RPM policy effective March 1, 2026. Coverage is now limited to three conditions:
-
Heart failure
-
Hypertension
-
Diabetes
In addition, reimbursement is limited to the original CPT code set: 99453, 99454, 99457, and 99458. The two codes finalized in the 2026 PFS (CPT 99445 and 99470) are explicitly listed by Aetna as non-covered, as are all RTM codes including 98975 and related codes.
Crucially, Aetna’s revised RPM policy applies to both commercial and Medicare Advantage (MA) members.
A Fair Starting Point: Most RPM Patients Aren't Losing Anything
Before examining the conflict this policy creates, it is worth acknowledging what it gets right. From a commercial standpoint, prioritizing high-prevalence, high-cost chronic conditions with strong RPM evidence is a defensible position.
The overwhelming majority of patients who derive the most measurable benefit from RPM have conditions that Aetna is continuing to cover: heart failure, hypertension, and diabetes. The clinical literature supporting remote monitoring of these conditions is substantial. For practices whose RPM programs are centered on these core populations, Aetna's updated policy aligns with clinical reality and does not represent a material disruption to care.
The Conflict: Remote Care Innovation vs. Restriction
While Aetna’s desire for evidence-based boundaries is a reasonable evolution for a commercial insurer, it stands in direct contrast to the CMS philosophy of encouraging new applications for remote care.
When CMS established the RPM framework, the approach was deliberately permissive. There was no condition-specific approved list because the goal was to encourage innovation and access across the entire clinical spectrum. CMS understood that by allowing clinicians to incorporate remote monitoring wherever they saw value, the industry would naturally discover the next generation of life-saving applications.
Aetna’s policy, by contrast, treats the current evidence base as a ceiling rather than a floor. By excluding conditions like chronic obstructive pulmonary disease (COPD) and hypertensive disorders of pregnancy where research is active and promising, Aetna risks stifling the very innovation that CMS is trying to catalyze. The clinical picture for RPM is not static, and we encourage Aetna and other commercial payers to revisit coverage decisions as additional evidence emerges.
Compliance With Medicare Advantage
The argument for Medicare Advantage compliance is the most significant hurdle for Aetna’s new policy. MA plans are contractually obligated to offer the same scope of benefits as traditional Medicare. Since Medicare covers RPM for the management of chronic conditions broadly, and has fully adopted the 2026 expanded code set, Aetna's condition-specific restrictions and code exclusions lack a regulatory basis for its MA products. This constitutes a direct conflict with CMS coverage requirements that providers must be prepared to navigate.
The UnitedHealthcare Precedent
We have seen this play out before. In late 2025, UnitedHealthcare (UHC) announced plans to restrict RPM coverage to just heart failure and hypertensive disorders of pregnancy, notably excluding essential hypertension and diabetes. The response from the provider community and organizations like Prevounce was immediate. The argument that these restrictions violated MA compliance proved so substantive that UHC delayed implementation indefinitely.
Aetna’s policy is more clinically sound than UHC’s was since Aetna correctly includes hypertension and diabetes, but the underlying legal conflict regarding MA remains identical.
Recommended Actions for Providers
Aetna's commercial policy does not alter the coverage entitlements of its Medicare Advantage members, and provider organizations should govern their RPM programs accordingly:
-
Do not apply coverage restrictions to Medicare Advantage patients. Aetna's three-condition limitation has no regulatory basis for MA members. The applicable coverage standard is CMS policy, which encourages monitoring for any acute or chronic condition.
-
Appeal all condition-based denials for MA patients. Claims denied on the basis of an "unapproved condition" should be appealed using the CMS coverage standard and MA "equivalent coverage" rules as a clear legal basis.
-
Engage Aetna ahead of the October 2026 policy review. Aetna’s policy bulletin identifies COPD and maternal health as promising but "unsupported" areas. Organizations with successful outcomes in these areas are well-positioned to present evidence that could expand these commercial boundaries during the next review.
-
Assess financial exposure. Model the revenue impact for your commercial Aetna population, particularly if your workflows rely on the newer 2026 codes that Aetna has declined to cover.
The Bigger Picture
Ultimately, the current remote patient monitoring environment is defined by a clear divergence between the push for innovation and access and the move toward more restricted coverage for conditions where there is an abundance of clinical evidence.
On the commercial side, Aetna’s policy is a sound and defensible step toward creating responsible boundaries for conditions where RPM's value is most undeniable. By correctly identifying hypertension, diabetes, and heart failure as core pillars of remote care, Aetna ensures its resources are targeted where they have the highest clinical impact. We would encourage Aetna to closely monitor emerging evidence for conditions like COPD and continue to update their policy as clinical consensus is established.
However, by applying any sort of restrictions to Medicare Advantage, Aetna runs a clear risk of non-compliance with federal standards. It is Medicare that continues to lead the charge for innovation, advocating for a healthcare future where tech-enabled care is limited only by a provider's clinical judgment.
Prevounce is here to help you navigate these shifts, ensuring your RPM program remains compliant while continuing to push the boundaries of what remote care can achieve. Follow us on LinkedIn or subscribe to our blog to stay up to date with the latest remote care management industry updates.